This update clarifies the title of Laura Lauman, who is president of ABI's proteomics and small molecule division.
NEW YORK (GenomeWeb News) — Applied Biosystems, MDS Sciex, Pfizer, and Sound Analytics plan to develop software that will work with high-throughput automation technology to improve compound analysis.
The technology will focus on improving techniques for analyzing absorption, distribution, metabolism, and excretion.
By improving the “timeliness and accuracy” of information drawn from ADME testing, ABI said, the new software would increase the efficiency of the pre-clinical drug-development process.
Pfizer R&D Director Cornelis Hop said that because a swift analysis of the characteristics of compounds is a “major challenge in drug discovery,” drug makers “need a new approach that delivers rapid turnaround of ADME-related assay data.”
Laura Lauman, president of ABI's proteomics and small molecule division, said that the end goal of the project is to help drug makers kill bad compounds early and often.